GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Design Therapeutics Inc (NAS:DSGN) » Definitions » PE Ratio (TTM)

DSGN (Design Therapeutics) PE Ratio (TTM) : At Loss (As of Dec. 12, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Design Therapeutics PE Ratio (TTM)?

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2024-12-12), Design Therapeutics's share price is $6.81. Design Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.85. Therefore, Design Therapeutics's PE Ratio (TTM) for today is At Loss.


The historical rank and industry rank for Design Therapeutics's PE Ratio (TTM) or its related term are showing as below:

DSGN' s PE Ratio (TTM) Range Over the Past 10 Years
Min: At Loss   Med: At Loss   Max: At Loss
Current: At Loss



DSGN's PE Ratio (TTM) is ranked worse than
100% of 246 companies
in the Biotechnology industry
Industry Median: 27.425 vs DSGN: At Loss

Design Therapeutics's Earnings per Share (Diluted) for the three months ended in Sep. 2024 was $-0.23. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.85.

As of today (2024-12-12), Design Therapeutics's share price is $6.81. Design Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.85. Therefore, Design Therapeutics's PE Ratio without NRI for today is At Loss.

Design Therapeutics's EPS without NRI for the three months ended in Sep. 2024 was $-0.23. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.85.

During the past 3 years, the average EPS without NRI Growth Rate was -97.70% per year.

During the past 5 years, Design Therapeutics's highest 3-Year average EPS without NRI Growth Rate was -97.70% per year. The lowest was -147.70% per year. And the median was -122.70% per year.

Design Therapeutics's EPS (Basic) for the three months ended in Sep. 2024 was $-0.23. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.85.


Design Therapeutics PE Ratio (TTM) Historical Data

The historical data trend for Design Therapeutics's PE Ratio (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Design Therapeutics PE Ratio (TTM) Chart

Design Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
PE Ratio (TTM)
N/A N/A At Loss At Loss At Loss

Design Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
PE Ratio (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss At Loss

Competitive Comparison of Design Therapeutics's PE Ratio (TTM)

For the Biotechnology subindustry, Design Therapeutics's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Design Therapeutics's PE Ratio (TTM) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Design Therapeutics's PE Ratio (TTM) distribution charts can be found below:

* The bar in red indicates where Design Therapeutics's PE Ratio (TTM) falls into.



Design Therapeutics PE Ratio (TTM) Calculation

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Design Therapeutics's PE Ratio (TTM) for today is calculated as

PE Ratio (TTM)=Share Price/Earnings per Share (Diluted) (TTM)
=6.81/-0.850
=At Loss

Design Therapeutics's Share Price of today is $6.81.
Design Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.85.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PE Ratio (TTM)=Market Cap /Net Income

There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


Design Therapeutics  (NAS:DSGN) PE Ratio (TTM) Explanation

The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.

If a company loses money, the PE Ratio (TTM) becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.

Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio (TTM) measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .

PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).


Design Therapeutics PE Ratio (TTM) Related Terms

Thank you for viewing the detailed overview of Design Therapeutics's PE Ratio (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


Design Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
6005 Hidden Valley Road, Suite 110, Carlsbad, CA, USA, 92011
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
Executives
Arsani William director C/O DESIGN THERAPEUTICS, INC., 6005 HIDDEN VALLEY ROAD, SUITE 110, CARLSBAD CA 92011
John P. Schmid director 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Heather Behanna director C/O ENTASIS THERAPEUTICS HOLDINGS INC., 35 GATEHOUSE DRIVE, WALTHAM MA 02451
Rodney W Lappe director C/O MIRATI THERAPEUTICS INC., 4660 LA JOLLA VILLAGE DRIVE, SUITE 500, SAN DIEGO CA 92121
Deepa Prasad director C/O VTV THERAPEUTICS INC., 3980 PREMIER DRIVE, SUITE 310, HIGH POINT NC 27265
Joao Md Siffert director, officer: President and CEO 20 ENTERPRISE, SUITE 200, ALISO VIEJO CA 92656
Simeon George director, 10 percent owner 161 WASHINGTON STREET, SUITE 500, CONSHOHOCKEN PA 19428
Sr One Capital Fund I Aggregator Lp 10 percent owner C/O DESIGN THERAPEUTICS, INC., 6005 HIDDEN VALLEY ROAD, SUITE 110, CARLSBAD CA 92011
Stella Xu director, 10 percent owner C/O ARMO BIOSCIENCES, INC., 575 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Julie Burgess officer: Chief Accounting Officer C/O DESIGN THERAPEUTICS, INC., 6005 HIDDEN VALLEY ROAD, SUITE 110, CARLSBAD CA 92011
Dawn Giangiulio officer: Principal Accounting Officer C/O DESIGN THERAPEUTICS, INC., 6005 HIDDEN VALLEY ROAD, SUITE 110, CARLSBAD CA 92011
Sean Jeffries officer: Chief Operating Officer C/O DESIGN THERAPEUTICS, INC., 6005 HIDDEN VALLEY ROAD, SUITE 110, CARLSBAD CA 92011
Justin Thacker officer: Vice President, Finance C/O DESIGN THERAPEUTICS, INC., 6005 HIDDEN VALLEY ROAD, SUITE 110, CARLSBAD CA 92011
Pratik Shah director, officer: Executive Chairperson 3366 N. TORREY PINES COURT, SUITE 220, LA JOLLA CA 92037
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116